MetaCap

Eton Pharmaceuticals (ETON) vs Schrodinger (SDGR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Eton Pharmaceuticals (ETON) has outperformed Schrodinger (SDGR) over the past year, gaining 269.7% versus a gain of 39.2%. Over five years, ETON leads with a +1341.9% price change compared with -42.0% for SDGR. Eton Pharmaceuticals is the larger company by market cap ($1.76 billion vs $1.72 billion), about 1.0 times the size.

Eton Pharmaceuticals converts more of its revenue into profit, with a net margin of -5.8% versus -40.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ETON+269.68%SDGR+39.22%
+333%+141%-50%
Nov 21, 20251 yearNov 20, 2026
ETON+1234.43%SDGR-43.80%
+1371%+615%-142%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ETON versus SDGR key metrics
MetricETONSDGR
Share price$60.85$22.93
Market cap$1.76B$1.72B
1-day change-0.83%-12.95%
YTD return+259.85%+28.24%
1-year return+269.68%+39.22%
5-year return+1341.94%-42.01%
P/E ratio (TTM)39.51—
Forward P/E18.41—
EPS (TTM)$1.54$-0.79
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$79.95M$255.87M
Revenue growth (YoY)+104.94%+23.29%
Net income (latest FY)$-4.60M$-103.27M
Gross margin53.46%55.74%
Operating margin-1.06%-65.23%
Net margin-5.75%-40.36%
52-week high$70.64$34.00
52-week low$14.27$10.95
Distance from 52-week high-13.86%-32.56%
Analyst consensusstrong_buybuy
Avg. price target upside+32.70%+46.40%
Average volume570.79K2.08M
Shares outstanding28.84M65.91M
Employees44850
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ETON has outperformed SDGR by 230.5 percentage points over the past year.
  • Eton Pharmaceuticals is more profitable, keeping -5.8 cents of every revenue dollar as net income versus -40.4 cents for Schrodinger.
  • Eton Pharmaceuticals grew revenue faster in its latest fiscal year (+104.94% vs +23.29%).

About Eton Pharmaceuticals

ETON stock →

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.

Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees

About Schrodinger

SDGR stock →

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.

Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees

ETON vs SDGR FAQ

Which is bigger, Eton Pharmaceuticals or Schrodinger?

Eton Pharmaceuticals (ETON) is larger, with a market capitalization of $1.76B compared with $1.72B for Schrodinger (SDGR).

Which stock has performed better over the past year, ETON or SDGR?

ETON returned +269.68% over the past 12 months, compared with +39.22% for SDGR (price return, excluding dividends). Past performance does not predict future results.

Are Eton Pharmaceuticals and Schrodinger in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons